Cover Image

Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy to reduce screen failures

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Raj Vuppalanchi, Rohit Loomba, Arun J. Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A. Robins, Bram Brouwers, Mark L. Hartman
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
by: Raj Vuppalanchi, et al.
Published: (2025)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
by: Nobuharu Tamaki, et al.
Published: (2024)

Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply
by: Maral Amangurbanova, et al.
Published: (2024)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
by: Federica Tavaglione, et al.
Published: (2025)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
by: Luis Antonio Díaz, et al.
Published: (2025)

A Message From the Editors
by: Colin W. Howden, et al.
Published: (2024)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
by: Sai Kiran Kuchana, et al.
Published: (2026)

Effects of Resmetirom on Metabolic‐Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon‐Like Peptide‐1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO ‐ NASH Trial
by: Mazen Noureddin, et al.
Published: (2025)

Clinical Trial: Semaglutide Versus Placebo in NIT ‐Assessed MASH —A Multicenter Randomised Placebo‐Controlled Trial ( SAMARA )
by: Veeral Ajmera, et al.
Published: (2026)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
by: Brent A. Neuschwander‐Tetri, et al.
Published: (2025)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
by: Nabil Noureddin, et al.
Published: (2024)

Research Communication: Real‐World Clinical Experience With Seladelpar in Primary Biliary Cholangitis
by: Selena Z. Kuo, et al.
Published: (2025)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
by: Carolin V. Schneider, et al.
Published: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
by: Samer Gawrieh, et al.
Published: (2024)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
by: Maryam Zafer, et al.
Published: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
by: Luis Antonio Díaz, et al.
Published: (2025)

Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
by: Donghee Kim, et al.
Published: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
by: Donghee Kim, et al.
Published: (2025)

Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
by: Rutao Lin, et al.
Published: (2024)

Clinical Trial: Plozasiran Prevents Recurrent Pancreatitis in Adults With Very Severe Hypertriglyceridemia—Results of a Post Hoc Analysis of the Phase 3 PALISADE Study
by: Rohit Loomba, et al.
Published: (2026)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
by: Carolin V. Schneider, et al.
Published: (2024)

A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
by: Nikita Mittal, et al.
Published: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
by: Nobuharu Tamaki, et al.
Published: (2024)

Editorial: Defining corticosteroid use in clinical trials
by: J. Siffledeen
Published: (2024)

Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and MASH Resolution
by: Matheus Souza, et al.
Published: (2026)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
by: Elliot B. Tapper, et al.
Published: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
by: María Hernández‐Pérez, et al.
Published: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
by: Richie Manikat, et al.
Published: (2024)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
by: Takao Miwa, et al.
Published: (2026)

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis ‐ prevalence, clinical impact, economic implications and management strategies
by: Pegah Golabi, et al.
Published: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
by: Mohamad Jamalinia, et al.
Published: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
by: Mingsi Zhang, et al.
Published: (2024)

Clinical trial: The effectiveness of long‐acting somatostatin analogue for output reduction of high‐output intestinal fistula or small bowel enterostomy. A randomised controlled trial
by: Allard S. Timmer, et al.
Published: (2024)

Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening
by: Timothy McAuliffe, et al.
Published: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
by: Lana Bridi, et al.
Published: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
by: Rocio Enriquez, et al.
Published: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
by: Elliot B. Tapper, et al.
Published: (2024)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky. Authors' Reply
by: Raj Vuppalanchi, et al.
Published: (2025)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Maral Amangurbanova, et al.
Published: (2024)